Alternative splicing for diseases, cancers, drugs, and databases

40Citations
Citations of this article
120Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Alternative splicing is a major diversification mechanism in the human transcriptome and proteome. Several diseases, including cancers, have been associated with dysregulation of alternative splicing. Thus, correcting alternative splicing may restore normal cell physiology in patients with these diseases. This paper summarizes several alternative splicing-related diseases, including cancers and their target genes. Since new cancer drugs often target spliceosomes, several clinical drugs and natural products or their synthesized derivatives were analyzed to determine their effects on alternative splicing. Other agents known to have modulating effects on alternative splicing during therapeutic treatment of cancer are also discussed. Several commonly used bioinformatics resources are also summarized. © 2013 Jen-Yang Tang et al.

Cite

CITATION STYLE

APA

Tang, J. Y., Lee, J. C., Hou, M. F., Wang, C. L., Chen, C. C., Huang, H. W., & Chang, H. W. (2013). Alternative splicing for diseases, cancers, drugs, and databases. The Scientific World Journal. https://doi.org/10.1155/2013/703568

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free